<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Repoussis, P.</style></author><author><style face="normal" font="default" size="100%">Zomas, A.</style></author><author><style face="normal" font="default" size="100%">Katodritou, E.</style></author><author><style face="normal" font="default" size="100%">Kyrtsonis, M.C.</style></author><author><style face="normal" font="default" size="100%">Delibasi, S.</style></author><author><style face="normal" font="default" size="100%">Vassou, A.</style></author><author><style face="normal" font="default" size="100%">Pouli, A.</style></author><author><style face="normal" font="default" size="100%">Zervas, K.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Maniatis, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Haematologica</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Elderly</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalidomide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644533213&amp;partnerID=40&amp;md5=2e48899d0d662de9f7d5a199b4f2835c</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">91</style></volume><pages><style face="normal" font="default" size="100%">252 - 254</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Fifty patients with multiple myeloma ≥75 years of age received primary treatment with melphalan (M) 8 mg/m2 on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20. This regimen was repeated every 5 weeks for three courses. Patients without evidence of disease progression received nine additional courses of MDT, but without DT on days 17-20, every 5 weeks. Sixty-two percent of patients achieved a partial response and 10% a complete response. The median time to response was 2 months. The median time to progression for all patients was 21.2 months. Deep venous thrombosis and peripheral neuropathy each occurred in 9% of patients. ©2006 Ferrata Storti Foundation.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :37Export Date: 21 February 2017</style></notes></record></records></xml>